Research analysts at StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) in a note issued to investors on Friday. The firm set a “sell” rating on the stock.
Ayala Pharmaceuticals Trading Down 10.4 %
NASDAQ ADXS opened at $0.56 on Friday. The firm has a market capitalization of $6.02 million, a PE ratio of -0.07 and a beta of 1.63. The business’s 50-day moving average price is $0.65 and its two-hundred day moving average price is $0.72. Ayala Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $1.95.
Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) last announced its earnings results on Tuesday, April 16th. The company reported ($2.96) earnings per share for the quarter.
Ayala Pharmaceuticals Company Profile
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
See Also
- Five stocks we like better than Ayala Pharmaceuticals
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Roblox: The Bottom Just Fell Out of the Metaverse
- What Are Dividend Contenders? Investing in Dividend Contenders
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
